Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05464069 · ClinicalTrials.gov registry record
Safety of Nerivio in Pregnant Women With Migraine
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 145
- Enrollment target
NCT05464069 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 145 participants.
The verdict
NCT05464069 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica's user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is based on an e-Survey including an e-eligibility questionnaire, an e-ICF ande-Questionnaire. Participants will be compensated for their time.
Interventions
- DEVICE Nerivio
- DRUG Migraine Relief
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2022-12-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05464069
The ClinicalTrials.gov registry entry for NCT05464069 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nerivio is the first listed.
NCT05464069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05464069 about?
NCT05464069 is a clinical study titled "Safety of Nerivio in Pregnant Women With Migraine". This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with...
What is the current status of trial NCT05464069?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2022-08-01. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05464069?
The interventions under investigation include: Nerivio (DEVICE), Migraine Relief (DRUG).
Who is sponsoring clinical trial NCT05464069?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.